Dermata Therapeutics Warrant Stock Performance
| DRMAW Stock | USD 0.01 0 19.57% |
Dermata Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -8.32, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Dermata Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Dermata Therapeutics is expected to outperform it. Use Dermata Therapeutics maximum drawdown and the relationship between the expected short fall and period momentum indicator , to analyze future returns on Dermata Therapeutics.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan | 12/10/2024 |
| Begin Period Cash Flow | 6.2 M |
Dermata |
Dermata Therapeutics Relative Risk vs. Return Landscape
If you would invest 1.00 in Dermata Therapeutics Warrant on September 13, 2024 and sell it today you would earn a total of 0.10 from holding Dermata Therapeutics Warrant or generate 10.0% return on investment over 90 days. Dermata Therapeutics Warrant is currently producing 1.9515% returns and takes up 18.1087% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Dermata, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Dermata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dermata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dermata Therapeutics Warrant, and traders can use it to determine the average amount a Dermata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1078
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | DRMAW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 18.11 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.95 actual daily | 38 62% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Dermata Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dermata Therapeutics by adding it to a well-diversified portfolio.
Dermata Therapeutics Fundamentals Growth
Dermata Stock prices reflect investors' perceptions of the future prospects and financial health of Dermata Therapeutics, and Dermata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermata Stock performance.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) | ||||
| Total Debt | 1.62 M | ||||
| Book Value Per Share | 24.25 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Total Asset | 7.98 M | ||||
| Retained Earnings | (53.39 M) | ||||
| Working Capital | 6.36 M | ||||
About Dermata Therapeutics Performance
Evaluating Dermata Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dermata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.27) | (1.33) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.23) | (1.29) |
Things to note about Dermata Therapeutics performance evaluation
Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dermata Therapeutics is way too risky over 90 days horizon | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics appears to be risky and price may revert if volatility continues | |
| Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan |
- Analyzing Dermata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dermata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermata Therapeutics' stock. These opinions can provide insight into Dermata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.